These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
66 related items for PubMed ID: 7664273
1. Expression of the p16 and p15 cyclin-dependent kinase inhibitors in lymphocyte activation and neuronal differentiation. Lois AF, Cooper LT, Geng Y, Nobori T, Carson D. Cancer Res; 1995 Sep 15; 55(18):4010-3. PubMed ID: 7664273 [Abstract] [Full Text] [Related]
2. Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Li YJ, Hoang-Xuan K, Delattre JY, Poisson M, Thomas G, Hamelin R. Oncogene; 1995 Aug 03; 11(3):597-600. PubMed ID: 7630644 [Abstract] [Full Text] [Related]
3. Genomic structure, expression and mutational analysis of the P15 (MTS2) gene. Stone S, Dayananth P, Jiang P, Weaver-Feldhaus JM, Tavtigian SV, Cannon-Albright L, Kamb A. Oncogene; 1995 Sep 07; 11(5):987-91. PubMed ID: 7675459 [Abstract] [Full Text] [Related]
4. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Sonoda Y, Yoshimoto T, Sekiya T. Oncogene; 1995 Nov 16; 11(10):2145-9. PubMed ID: 7478535 [Abstract] [Full Text] [Related]
5. Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors. Zariwala M, Liu E, Xiong Y. Oncogene; 1996 Jan 18; 12(2):451-5. PubMed ID: 8570224 [Abstract] [Full Text] [Related]
6. Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors. Zariwala M, Xiong Y. Oncogene; 1996 Nov 07; 13(9):2033-8. PubMed ID: 8934552 [Abstract] [Full Text] [Related]
7. Deletion and transfection analysis of the p15/MTS2 gene in malignant gliomas. Tenan M, Benedetti S, Finocchiaro G. Biochem Biophys Res Commun; 1995 Dec 05; 217(1):195-202. PubMed ID: 8526910 [Abstract] [Full Text] [Related]
8. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Yoshida S, Todoroki T, Ichikawa Y, Hanai S, Suzuki H, Hori M, Fukao K, Miwa M, Uchida K. Cancer Res; 1995 Jul 01; 55(13):2756-60. PubMed ID: 7796400 [Abstract] [Full Text] [Related]
9. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Herman JG, Jen J, Merlo A, Baylin SB. Cancer Res; 1996 Feb 15; 56(4):722-7. PubMed ID: 8631003 [Abstract] [Full Text] [Related]
10. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Elisei R, Shiohara M, Koeffler HP, Fagin JA. Cancer; 1998 Nov 15; 83(10):2185-93. PubMed ID: 9827724 [Abstract] [Full Text] [Related]
11. A novel pre-B acute lymphoblastic leukemia cell line with chromosomal translocation between p16(INK4A)/p15(INK4B) tumor suppressor and immunoglobulin heavy chain genes: TGFbeta/IL-7 inhibitory signaling mechanism. Urashima M, Hoshi Y, Sugimoto Y, Kaihara C, Matsuzaki M, Chauhan D, Ogata A, Teoh G, DeCaprio JA, Anderson KC. Leukemia; 1996 Oct 15; 10(10):1576-83. PubMed ID: 8847892 [Abstract] [Full Text] [Related]
12. Association of CDKN2A/p16INK4A with human head and neck keratinocyte replicative senescence: relationship of dysfunction to immortality and neoplasia. Loughran O, Malliri A, Owens D, Gallimore PH, Stanley MA, Ozanne B, Frame MC, Parkinson EK. Oncogene; 1996 Aug 01; 13(3):561-8. PubMed ID: 8760298 [Abstract] [Full Text] [Related]
13. Consistent inactivation of p19(Arf) but not p15(Ink4b) in murine myeloid cells transformed in vivo by deregulated c-Myc. Haviernik P, Schmidt M, Hu X, Wolff L. Oncogene; 2003 Mar 20; 22(11):1600-10. PubMed ID: 12642863 [Abstract] [Full Text] [Related]
14. Association of rat p15INK4B/p16INK4 deletions with monosomy 5 in kidney epithelial cell lines but not primary renal tumors. Knapek DF, Serrano M, Beach D, Trono D, Walker CL. Cancer Res; 1995 Apr 15; 55(8):1607-12. PubMed ID: 7712460 [Abstract] [Full Text] [Related]
15. Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T-cell acute lymphoblastic leukemia. Omura-Minamisawa M, Diccianni MB, Batova A, Chang RC, Bridgeman LJ, Yu J, Pullen J, Bowman WP, Yu AL. Clin Cancer Res; 2000 Apr 15; 6(4):1219-28. PubMed ID: 10778944 [Abstract] [Full Text] [Related]
16. Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Gray-Bablin J, Rao S, Keyomarsi K. Cancer Res; 1997 Feb 15; 57(4):604-9. PubMed ID: 9044834 [Abstract] [Full Text] [Related]
17. Expression of cell cycle regulatory genes in chronic myelogenous leukemia. Iolascon A, Della Ragione F, Giordani L, Serra A, Saglio G, Faienza MF. Haematologica; 1998 Sep 15; 83(9):771-7. PubMed ID: 9825572 [Abstract] [Full Text] [Related]
18. Codeletion of p15 and p16 in primary malignant mesothelioma. Xio S, Li D, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA. Oncogene; 1995 Aug 03; 11(3):511-5. PubMed ID: 7630635 [Abstract] [Full Text] [Related]
19. Cell cycle regulators in bladder cancer: relationship to schistosomiasis. Eissa S, Ahmed MI, Said H, Zaghlool A, El-Ahmady O. IUBMB Life; 2004 Sep 03; 56(9):557-64. PubMed ID: 15590562 [Abstract] [Full Text] [Related]
20. Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines. Yaginuma Y, Hayashi H, Kawai K, Kurakane T, Saitoh Y, Kitamura S, Sengoku K, Ishikawa M. Exp Cell Res; 1997 Jun 15; 233(2):233-9. PubMed ID: 9194486 [Abstract] [Full Text] [Related] Page: [Next] [New Search]